Clinical trial · Observational
Screening and Validation of Serum Protein Biomarkers for Early Diagnosis of Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer (Diagnosis) | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Gastric cancer
- description
- Patients with histopathologically confirmed gastric cancer
- label
- Non Gastric Cancer
- description
- Healthy controls or patients with histologically confirmed precancerous gastric lesions that have not yet progressed to malignancy.
Primary outcomes (1)
- measure
- Diagnostic Performance of the Serum Protein Biomarker-Based Model for Gastric Cancer
- timeFrame
- 3 years
- description
- Evaluation of the sensitivity and specificity of a diagnostic model constructed using key serum protein biomarkers for the early detection of gastric cancer.
Secondary outcomes (3)
- measure
- Predictive performance of the serum protein model for the progression risk from precancerous gastric lesions to gastric cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria Gastric cancer patients enrolled in this study must meet all of the following criteria: 1. Male or female, aged ≥18 and ≤95 years. 2. Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer. 3. No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy). 4. Availability of complete clinicopathological data and follow-up information. Patients with precancerous gastric lesions must meet all of the following criteria: 1. Male or female, aged ≥18 and ≤95 years. 2. Histopathologically confirmed absence of gastric cancer. 3. Diagnosis consistent with precancerous gastric lesions as defined by the American Society for Gastrointestinal Endoscopy (ASGE, 2015 edition). 4. Availability of complete clinicopathological data and follow-up information. Healthy controls must meet all of the following criteria: 1. Male or female, aged ≥18 and ≤95 years. 2. Histopathologically confirmed absence of gastric cancer. 3. No evidence of precancerous gastric lesions. 4. Availability of complete clinicopathological data and follow-up information. Exclusion Criteria Patients meeting any of the following conditions will be excluded: 1. History of prior malignancy or cancer treatment. 2. Presence of concurrent malignancies of other types. 3. Inability to tolerate gastroscopy.
References
Publications (0)
Data not yet available